# Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

> **NCT05421325** · PHASE2 · RECRUITING · sponsor: **Qu Biologics Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Immune Deficiency

## Interventions

- **BIOLOGICAL:** QBKPN SSI
- **OTHER:** Normal Saline Placebo

## Key facts

- **NCT ID:** NCT05421325
- **Lead sponsor:** Qu Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-11
- **Primary completion:** 2025-09
- **Final completion:** 2026-02
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05421325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05421325, "Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05421325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*